Merck (MRK) Announces First Clinical Outcomes Evaluating Six-Week Dosing Schedule for KEYTRUDA Presented at AACR

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Merck (MRK) Announces First Clinical Outcomes Evaluating Six-Week Dosing Schedule for KEYTRUDA Presented at AACR

First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I

April 27, 2020 6:55 AM EDT

Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six Weeks (Q6W) Comparable to Approved 200 mg Every Three Weeks (Q3W) Regimen

Resubmitted Supplemental Biologics License Applications (sBLAs) for KEYTRUDA Q6W Dosing Under Review with US FDA Across All Approved Adult Indications

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from Cohort B of KEYNOTE-555, a Phase 1 trial evaluating a 400 mg every six-week (Q6W)... More